Filed with ASX · · 3 pages · English
Tetratherix Limited has announced the successful completion of a preclinical validation study for TegenEOS, a carrier for platelet-rich plasma (PRP) in tendon repair, which showed positive results in healing injuries better than PRP alone. The study demonstrated that injuries treated with TegenEOS + PRP exhibited organized new blood vessels and reduced inflammation compared to those treated with PRP alone. TegenEOS is designed to hold PRP at the injury site, addressing the common issue of PRP dispersing quickly after injection, which limits its effectiveness. The results support further development of TegenEOS as a dual-purpose product for both bone grafts and biologics delivery in orthopaedics.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Release ASX:TTX TegenEOS+PRP Opens Orthopaedic Pathway with Positive Tendon Repair Data 29th October 2026 HIGHLIGHTS TTX is pleased to announce the successful completion of its ten-week preclinical validation study of TegenEOS as a carrier for platelet-rich plasma (PRP) in tendon repair. More...
Follow Tetratherix into a list and get an email when it puts out news.
Follow Tetratherix